Headlines

Novo Nordisk (NOVOB DC) announced first results from the STEP Young phase 3 trial; The trial met its primary endpoint, demonstrating superior body mass index reduction at week 68

Newsquawk Staff ·

Novo Nordisk (NOVOB DC) announced first results from the STEP Young phase 3 trial; The trial met its primary endpoint, demonstrating superior body mass index reduction at week 68.

Sources

Related headlines